| Data set | Procedure | What's in this data set | Panel | Sex | Age (weeks) | Year |
|---|---|---|---|---|---|---|
|
|
body weight
with arsenic |
Baseline, then after iAs exposure for 26 wks | DO population | m | 4-34 wks | 2022 |
|
|
hormone quantification
with arsenic |
Blood insulin following 6 h fast, and after intraperitoneal glucose injection; at baseline and after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
intake monitoring
with arsenic |
Food and water consumption, at baseline then at 1 to 4 wk intervals after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
metabolic panel
with arsenic |
Blood glucose following 6 h fast, and after intraperitoneal glucose injection; at baseline and after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
metabolite quantification
with arsenic |
iAs quantification in urine and liver, at 24 and 26 wks after iAs exposure. IAs speciation evaluated specifically monomethyl-arsenic acid (MMA) and dimethyl-arsenic acid (DMA) | DO population | m | 4-34 wks | 2022 |
|
|
MRI
with arsenic |
Fat and lean tissue mass at baseline, and 12 and 24 wks after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
urinalysis
with arsenic |
Urine volume at baseline, and 12 and 24 wks after iAs exposure | DO population | m | 4-34 wks | 2022 |